Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Selinexor and Docetaxel in Treating Participants with Stage IV KRAS Mutant Non-Small Cell Lung Cancer

Multiple Cancer Types

This phase I / II trial studies the safety and best dose of selinexor and docetaxel in treating participants with stage IV KRAS-mutation non-small cell lung cancer that has spread to other places in the body. Selinexor may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving selinexor and docetaxel may work better in treating participant with stage IV KRAS mutant non-small cell lung cancer.
Lung, Non Small Cell
I/II
York, Sally
NCT03095612
VICCTHO1791

Pevonedistat and Azacitidine in Treating Patients with Refractory or Relapsed Myelodysplastic Syndrome or Myelodysplastic Syndrome / Myeloproliferative Neoplasm Who Fail Primary Therapy

Myelodysplastic Syndrome

This phase II trial studies how well pevonedistat and azacitidine work in treating patients with myelodysplastic syndrome or myelodysplastic syndrome / myeloproliferative neoplasm that has failed primary therapy, that does not respond to treatment (refractory), or has come back (recurrent). Pevonedistat and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Myelodysplastic Syndrome
II
Savona, Michael
NCT03238248
VICCHEM16146

A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors

Multiple Cancer Types

This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.
Bladder, Cervical, Esophageal, Head/Neck, Lung, Non Small Cell, Phase I, Uterine
I
Berlin, Jordan
NCT03854227
VICCPHI1909

Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC

Breast

This is a phase Ib / II Study of Leronlimab (PRO 140) combined with Carboplatin in Patients with CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC). Study population will consist of patients with CCR5-positive, locally advanced or metastatic triple-negative breast cancer (mTNBC) who are naïve to chemotherapy in metastatic setting but have been exposed to anthracyclines and taxane in neoadjuvant and adjuvant settings (first-line).
Breast
I/II
Abramson, Vandana
NCT03838367
VICCBREP1983

A Study of ALX148 With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)

Myelodysplastic Syndrome

This Phase 1 / 2 clinical study will evaluate ALX148 in combination with azacitidine for the treatment of patients with higher risk myelodysplastic syndrome (MDS).
Myelodysplastic Syndrome
I/II
Byrne, Michael
NCT04417517
VICCHEMP2084

Impact of Indwelling Tunneled Pleural Drainage Systems (Gravity or Vacuum Based) on Pain in Patients with Recurrent Pleural Effusions

Lung

This trial studies the impact of indwelling tunneled pleural drainage systems (gravity or vacuum based) on pain in patients with plural effusion that has come back (recurrent). Vacuum drainage and gravity drainage are two commonly used drainage methods. Studying the best drainage methods may help future patients undergoing indwelling tunneled pleural catheter placement.
Lung
N/A
Maldonado, Fabien
NCT03831386
VICCTHO19118

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Multiple Myeloma

The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab with or without pomalidomide) and to characterize the safety of each RP2D for selected treatment combinations.
Multiple Myeloma
I
Dholaria, Bhagirathbhai
NCT04108195
VICCHEMP1995

Phase 1b / 2 Study of Rivoceranib and Trifluridine / Tipiracil for Metastatic Colorectal Cancer

Multiple Cancer Types

Comparing the efficacy of rivoceranib and trifluridine / tipiracil administered individually as monotherapies, as well as a rivocernib plus trifluridine / tipiracil combination therapy in the treatment of mCRC that is unresponsive to traditional chemotherapies.
Colon, Rectal
I/II
Eng, Cathy
NCT04073615
VICCGI1970

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Multiple Cancer Types

This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent IDH inhibitor, in patients with IDH1 or IDH2-mutant advanced hematologic malignancies who have received standard therapy
Hematologic, Leukemia, Myelodysplastic Syndrome, Phase I
I
Byrne, Michael
NCT04603001
VICCHEMP2061

Rucaparib and Nivolumab in Treating Patients with Advanced or Metastatic Biliary Tract Cancer after Platinum Therapy

Multiple Cancer Types

This phase II trial studies how well rucaparib and nivolumab work in treating patients with biliary tract cancer that has spread to other places in the body after platinum therapy. Rucaparib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving rucaparib and nivolumab after platinum therapy may help kill more cancer cells that are left after chemotherapy.
Gastrointestinal, Liver
II
Goff, Laura
NCT03639935
VICCGI1915

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: